Compare Medpace Holdings Inc (MEDP) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.29 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is the larger of the two by market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,178,312). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| MEDP | VOOG | |
|---|---|---|
Market Cap | $16.82B | $27.10B |
Volume | 223,093 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $87.81 |
52-Week Low | $393.42 | $65.32 |
Typical Hold Time | 14 Days | 54 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
VOOG trades at $87.29, down 0.46% on the day, maintaining a bullish technical stance with strong moving average support. The ETF holds 148 large-cap growth stocks from the S&P 500, with significant technology sector exposure. Recent institutional buying activity from firms like Integrated Wealth Concepts and NewEdge Advisors signals confidence in the growth-focused strategy. Technical indicators show bullish momentum with key support at $85 and resistance at $88.
VOOG's long-term growth potential remains compelling with 400% returns over the past decade and 14% gains year-to-date. The ETF's low 0.07% expense ratio and focus on high-performing growth stocks provide cost-effective exposure to market leaders. However, concentration in technology stocks and sensitivity to interest rate changes present risks. The current neutral oscillator readings suggest potential for consolidation near recent highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
